Progesterone receptor (PR) governs estrogen signaling in ER+/PR+ breast cancers by dictating chromatin binding of estrogen receptor alpha (ER) [1–3] and modulating the bioavailability of molecules needed for tumor growth [4]. The gene discussed is ESR1; the disease is neoplasm.